Bone quality and osteoporosis therapy (Q37756589)

22 August 2017

1 reference

title

Bone quality and osteoporosis therapy (English)

1 reference

22 August 2017

0 references

Regina Matsunaga Martin

series ordinal

1

1 reference

PubMed ID

20485908

22 August 2017

Pedro Henrique S Correa

series ordinal

2

1 reference

22 August 2017

1 March 2010

1 reference

Arquivos Brasileiros de Endocrinologia e Metabologia

22 August 2017

1 reference

22 August 2017

54

1 reference

22 August 2017

186-199

1 reference

22 August 2017

2

1 reference

Osteoporosis: diagnosis and management today and tomorrow

22 August 2017

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Diagnosis of osteoporosis and assessment of fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Identification of osteopenic women at high risk of fracture: the OFELY study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Bone quality: getting closer to a definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

In vivo high resolution MRI of the calcaneus: differences in trabecular structure in osteoporosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Bone ultrastructure: evolution during osteoporosis and aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Is bone quality associated with collagen age?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Chemical makeup of microdamaged bone differs from undamaged bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Bone microdamage and skeletal fragility in osteoporotic and stress fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Bone microdamage: a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Positive effects of intravenous zoledronic acid on bone remodeling and structure: are different effects on osteoblast activity to other oral bisphosphonates responsible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Raloxifene enhances vertebral mechanical properties independent of bone density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Parathyroid hormone and periosteal bone expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Strontium ranelate: new perspectives for the management of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Strontium ranelate: a physiological approach for an improved bone quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Postmenopausal hormone replacement therapy: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

The effects of hormone replacement therapy on cortical bone in postmenopausal women. A histomorphometric study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Effect of hormone replacement therapy on bone quality in early postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Selective modification of bone quality by PTH, pamidronate, or raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Clinical perspectives on bone quality in osteoporosis: effects of drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Determinants of skeletal fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

Bone quality: the material and structural basis of bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

A biomechanical perspective on bone quality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200015

10.1590/S0004-27302010000200015

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20485908